SEC Form 4/A · accession 0001140361-18-011728
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Christophe Navarre
Director
Period of report
Jun 28, 2017
Accepted (ET)
Mar 2, 2018 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $10.51 | Jun 28, 2017 | A | 35,000 | A | Jun 28, 2018 | Jun 28, 2022 | ADSs | 35,000 | 35,000 | D |
Explanation of responses
- F1Options become exercisable as to all 35,000 ADSs on the first anniversary of the 06/28/2017 grant date.
- F2The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
Remarks
This amendment to the Form 4 filed by the reporting person on June 30, 2017 (the "Previous Form 4") is being filed solely to correct the number of derivative securities acquired and the number of derivative securities beneficially owned following the transaction reported in Columns 5 and 9 of Table II of the Previous Form 4. The number of derivative securities in the Previous Form 4 was incorrectly listed as 30,000 and has been corrected to 35,000.